The antiviral drug remdesivir, marketed as Veklury, received full approval from the U.S. Food and Drug Administration (FDA) on October 20, 2020, to treat hospitalized COVID-19 patients aged 12 and older. According to the FDA announcement, the approval makes remdesivir the first and only fully approved pharmacological treatment for the disease caused by SARS-CoV-2.
Regulatory Milestones and Clinical Trial Evidence
The FDA granted the approval of Veklury based on data from several clinical trials that evaluated the drug’s efficacy in different patient populations. According to the National Institutes of Health (NIH), the pivotal ACTT-1 trial demonstrated that patients receiving remdesivir recovered faster than those receiving a placebo, cutting the median recovery time from 15 days down to 10 days. The agency also reviewed safety and efficacy data from the randomized, open-label trial known as SIMPLE, which evaluated varying treatment durations in patients with severe and moderate COVID-19.
Prior to full approval, the drug had been widely distributed under an Emergency Use Authorization (EUA) issued by the FDA on May 1, 2020. The updated regulatory status shifts remdesivir from experimental emergency access to a standard, commercially available therapeutic option for hospitals managing severe cases.
Dosage, Administration, and Patient Criteria
Under the approved labeling, Veklury is indicated for adults and pediatric patients aged 12 years and older who weigh at least 40 kilograms and require hospitalization for COVID-19. According to the drug manufacturer Gilead Sciences, administration requires an intravenous infusion under the supervision of a healthcare provider in a hospital or clinical setting equipped to monitor severe systemic reactions.
The standard treatment course consists of a 200-milligram loading dose on the first day, followed by 100-milligram maintenance doses administered daily for four days, totaling a five-day regimen. Physicians may extend the treatment duration up to 10 days for patients requiring mechanical ventilation or extracorporeal membrane oxygenation (ECMO).
Safety Profile and Warnings
Clinical evaluations indicate that remdesivir carries specific risks that require careful patient monitoring. According to the FDA prescribing information, known side effects include increased levels of liver enzymes, which can indicate liver injury. Healthcare providers are advised to perform liver function tests prior to initiating treatment and during the course of therapy as clinically appropriate.
Additionally, patients have reported hypersensitivity reactions, including infusion-related events such as low blood pressure, sweating, shivering, nausea, and wheezing. The label also warns against administering remdesivir simultaneously with chloroquine phosphate or hydroxychloroquine sulfate, as laboratory data suggest a potential reduction in the antiviral activity of remdesivir when combined with those drugs.
Therapeutic Comparison: Remdesivir vs. Supportive Care
| Parameter | Veklury (Remdesivir) | Standard Supportive Care |
|---|---|---|
| Regulatory Status | Fully approved by the FDA for hospitalized patients aged 12 and older. | Broadly utilized across all demographics based on clinical guidelines. |
| Primary Outcome | Shortens median recovery time to 10 days compared to placebo. | Manages symptoms, oxygen levels, and secondary complications without targeted antivirals. |
| Administration Method | Intravenous infusion requiring clinical oversight. | Includes oxygen therapy, prone positioning, and fluids as needed. |
Frequently Asked Questions
Who is eligible to receive remdesivir in a hospital setting?
According to the FDA, Veklury is authorized for hospitalized adult and pediatric patients aged 12 years and older who weigh at least 40 kilograms. Use is restricted to healthcare facilities capable of providing acute care comparable to inpatient hospital settings.
Does remdesivir cure COVID-19?
Clinical trials show that remdesivir inhibits viral replication, which helps reduce recovery times for hospitalized patients, but it is not classified as a total cure. Treatment is designed to lessen the severity of the illness and accelerate discharge from the hospital.
How is remdesivir administered to patients?
The drug is administered exclusively via intravenous (IV) infusion. The standard course lasts for five days, though physicians may adjust the duration depending on the patient’s clinical response and severity of illness.